Medical technology company iRhythm Technologies (NASDAQ: IRTC) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 25.7% year on year to $199.4 million. The company expects the full year’s revenue to be around $880 million, close to analysts’ estimates. Its non-GAAP loss of $0.35 per share was 45.3% above analysts’ consensus estimates.

Is now the time to buy IRTC? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

iRhythm’s first quarter saw a mix of strong financial performance and a muted market response, as revenue and adjusted profits surpassed Wall Street expectations. The company attributed its results to sustained demand for its ZioMonitor and Zio AT cardiac monitoring products, as well as operational improvements that drove margin expansion. CEO Quentin Blackford highlighted “broad-based growth across cardiology, primary care, innovative channels, and international markets,” while also noting progress in automating manufacturing and integrating workflows with electronic health records.

Looking ahead, iRhythm’s updated guidance is shaped by ongoing investments in artificial intelligence (AI), the coming launch of its next-generation monitoring products, and efforts to grow its footprint in adjacent markets like sleep diagnostics. Management pointed to the potential for efficiency gains from a new AI algorithm—expected to significantly reduce clinical review times—and the expansion of primary care as a referral source for cardiac monitoring. CFO Daniel Wilson noted, “We are raising guidance based on durable demand across our core and emerging channels, while remaining disciplined in our forecasts given early-year uncertainties.”

Key Insights from Management’s Remarks

Management pointed to several factors behind the quarter’s outperformance, including broad customer adoption, workflow integration, and the expanding use of AI across iRhythm’s product suite.

• Workflow and EHR integration: Over half of iRhythm’s monitoring volume now comes from accounts integrated with electronic health records (EHR), streamlining clinical workflows for primary care and specialty providers. This integration supports higher adoption and improves the efficiency of diagnostic processes, especially in primary care settings.

• AI-powered platform advancement: The company emphasized progress in developing a next-generation AI algorithm, trained on over 3 billion hours of ECG data. Management expects this algorithm to reduce technician review time by as much as 50%, which would support future gross margin expansion and operational efficiency across the ZioMonitor, Zio AT, and future Zio MCT products.

• Innovative and international channels: iRhythm highlighted traction in both innovative care models and international markets. In the UK, it reported its strongest quarter to date, and in Japan, a recent reimbursement update provided modest supplemental payments for longer-duration monitoring. The company continues to pilot its platform in adjacent markets like sleep diagnostics, positioning itself to enter new addressable markets over time.

• Regulatory and quality progress: Management reported completion of a comprehensive review of its quality management system in response to an FDA warning letter. An independent third-party review found no material observations, which iRhythm views as a positive step toward resolving ongoing regulatory concerns.

• Volume-led growth and margin leverage: The company credited its first-quarter margin improvement to manufacturing automation, operational discipline, and a land-and-expand model that drives efficient account growth. New accounts contributed significantly to overall volume growth, and management sees further opportunities for margin expansion as automation and AI are embedded more broadly.

Drivers of Future Performance

iRhythm’s outlook centers on driving volume growth and margin improvement through AI innovation, broader primary care reach, and disciplined investment amid evolving regulatory and market dynamics.

• AI algorithm deployment: Management expects the next-generation AI algorithm to become a key driver of operating leverage, with the potential to cut clinical review time and significantly enhance gross margins across the product suite. The algorithm’s deployment is tied to the launch of the new Zio MCT device, anticipated in 2027, but will also benefit existing products.

• Primary care and market expansion: The company is prioritizing upstream expansion, with a growing share of new patient monitoring originating in primary care. Management sees this as critical to expanding the total addressable market for arrhythmia detection. Early pilots in sleep diagnostics and continued engagement in international markets are also expected to provide incremental growth opportunities.

• Regulatory and reimbursement risks: Management cited ongoing regulatory reviews, including the FDA warning letter and evolving Medicare coverage policies, as areas of uncertainty. The company continues to work collaboratively with regulators, but timing and outcomes remain difficult to predict. International reimbursement improvements, particularly in Japan, are viewed as potential long-term catalysts but not yet material contributors.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will monitor (1) the FDA’s review outcome for iRhythm’s next-generation AI algorithm and Zio MCT device; (2) the pace of primary care adoption as a driver of volume growth; and (3) further reimbursement developments in international markets, particularly Japan. Progress in sleep diagnostics pilots and resolution of regulatory actions will also be important for tracking strategic execution.

iRhythm currently trades at $125.00, down from $129.16 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

High Quality Stocks for All Market Conditions

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.